AC Immune (ACIU) Equity Average (2017 - 2025)
AC Immune (ACIU) has disclosed Equity Average for 8 consecutive years, with $154.6 million as the latest value for Q4 2024.
- On a quarterly basis, Equity Average fell 13.26% to $154.6 million in Q4 2024 year-over-year; TTM through Dec 2024 was $154.6 million, a 13.26% decrease, with the full-year FY2024 number at $153.5 million, down 13.76% from a year prior.
- Equity Average was $154.6 million for Q4 2024 at AC Immune, down from $178.3 million in the prior quarter.
- In the past five years, Equity Average ranged from a high of $256.8 million in Q4 2020 to a low of $154.6 million in Q4 2024.
- A 5-year average of $209.6 million and a median of $213.5 million in 2022 define the central range for Equity Average.
- Peak YoY movement for Equity Average: rose 13.19% in 2020, then decreased 16.51% in 2023.
- AC Immune's Equity Average stood at $256.8 million in 2020, then fell by 4.61% to $245.0 million in 2021, then dropped by 12.85% to $213.5 million in 2022, then fell by 16.51% to $178.3 million in 2023, then fell by 13.26% to $154.6 million in 2024.
- Per Business Quant, the three most recent readings for ACIU's Equity Average are $154.6 million (Q4 2024), $178.3 million (Q4 2023), and $213.5 million (Q4 2022).